Dual-action cancer nanomedicine therapy

Description

A French-Australian research team has fabricated antibody-coated porous silicon nanoparticles that can actively target cells through binding to specific cell-surface receptors. They demonstrated that these nanoparticles can bind to and selectively deliver multiple therapeutics to human B cells in vitro.

By co-loading a chemotherapy drug with gold nanoclusters, the system took advantage of combined chemotherapy and hyperthermia therapy and provided synergistic effects in eradicating targeted cells.